Navigation Links
Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine
Date:2/3/2011

WORCESTER, Mass., Feb. 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com), announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.  The Company has previously received allowances of broad claims surrounding its Ii-Key hybrid technology, which was used in the design of the AE37 vaccine platform.  The current allowance strengthens independent composition of matter claims directed to the AE37 peptide. The full term of the new patent will extend through January 5, 2028.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)

AE37 is currently the subject of a randomized and controlled Phase II efficacy study in patients treated for breast cancer who are at high risk of recurrence.  Favorable results from this study have been reported previously.  This immunotherapeutic vaccine also has been tested in a Phase I study in patients with prostate cancer, which confirmed the safety and immunogenicity observed in the prior breast cancer study.  In addition to breast and prostate cancer, many other types of cancer, such as lung, colon, stomach and bladder, also express the HER2 protein, which is the target for an AE37 stimulated immune response.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs i
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
2. Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer
3. Generex Announces Extension of Global Medical Direct Acquisition Closing Date
4. Generex Receives New Patent for Buccal Drug Delivery Platform Technologies
5. Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal
6. Generex Oncology Awarded Two IRS Therapeutic Discovery Project Grants
7. Generex Common Stock Now Quoted on the Over-the-Counter Bulletin Board
8. Generex to Participate in Canadian Diabetes Association Conference
9. Generex Reschedules Live Video Webcast
10. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Now available for sale, The Armor1 Ankle Roll Guard is ... sprains by cushioning the ankle from an inversion or ... outside of any shoe type and allows the user ... protection against sprains. With customers in physical therapy, podiatry, ...
(Date:1/23/2015)... LAS VEGAS , Jan. 23, 2015 Cord Blood ... CBAI ) ("CBAI" or the "Company")  filed a Preliminary Proxy ... ( www.sec.gov ) today, and provides an update for shareholders ... authorized shares is requested. Dear Shareholders, ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... Calif., May 28 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... of voreloxin (formerly SNS-595) at two major upcoming,oncology ... Phase 2 clinical trial of,voreloxin in platinum-resistant ovarian ... Society of Clinical Oncology (ASCO) Annual Meeting,being held ...
... Albuferon(R) for hepatitis C and LymphoStat-B(R) for lupus on track for ... potential launch in 2010 -,- ABthrax(TM) for inhalation anthrax on track to ... and new ... - GSK to advance darapladib to Phase 3 for atherosclerosis ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress 2Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 4Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 5Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 6Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 7Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 8Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 9Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 10Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 11
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... in an effort to further promote visibility and adoption of ... long made AMA journals available via its subscription services, EBSCO ... Network. , Long known as both a subscription ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... , STAMFORD, Conn. and WESTON, Mass., Nov. 6 ... incorporate innovative and flexible elements into their business ... reform and maintain attractive long-term returns, according to ... Royalty Partners, a global healthcare private equity firm, ...
... Health Reform Bill Should Adopt Key Details of Successful ... Group , WASHINGTON, Nov. 6 Consumer Watchdog, ... law in California, praised Congress for including a key ... reform bill. Among amendments released this week is ...
... SEATTLE, Nov. 6 We Work for Health, an ... leaders, today released the results of a first-of-its-kind economic ... sector has passed many of the traditional resource-based industries ... in the same range of importance as some of ...
... than toilet seats, study finds , FRIDAY, Nov. 6 ... ships raises the risk of norovirus-caused gastrointestinal illness outbreaks, ... percent of acute gastroenteritis outbreaks that occur on cruise ... 66 ships monitored by the U.S. Centers for Disease ...
... ... conducting a lecture on Radiation Therapy Options For Patients Suffering From Mesothelioma. Her lecture will ... ... lecture on Tuesday November 10th, 2009, 5:30 pm CST, MesoCare.org is sponsoring a lecture by ...
... SHENZHEN, China, Nov. 6 /PRNewswire-Asia-FirstCall/ -- Mindray ... manufacturer and,marketer of medical devices worldwide, today announced that ... Medicine International Trade Fair with,Congress in Dusseldorf, Germany from ... will exhibit more than 40 devices from its three ...
Cached Medicine News:Health News:Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top 2Health News:Consumer Watchdog Hails House Cost-Control Plan to Regulate Health Insurance Rates, Urges Lawmakers to Combine It With Strong 'Public Option' 2Health News:Consumer Watchdog Hails House Cost-Control Plan to Regulate Health Insurance Rates, Urges Lawmakers to Combine It With Strong 'Public Option' 3Health News:Consumer Watchdog Hails House Cost-Control Plan to Regulate Health Insurance Rates, Urges Lawmakers to Combine It With Strong 'Public Option' 4Health News:New Study: Life Science Jobs Total 77,000 in Washington State 2Health News:New Study: Life Science Jobs Total 77,000 in Washington State 3Health News:Poor Restroom Cleaning Causes Cruise-Ship Sickness 2Health News:Mindray Medical to Exhibit at MEDICA 2009 in Dusseldorf, Germany 2
... IEC60601-2-51 new international standard for ... digital filter performance. It is ... 12 channel interpretive electrocardiograph.,It features ... records 3, 4, 6 or ...
The Sonic WAVE™is the first market-ready Alternative to Ultrasound...
... robust, compact Sleepscan Traveler provides the ultimate ... acquire PSG data in the home, a ... Traveler sleep studies utilize the same powerful ... studies. Sleepscan Traveler studies take full advantage ...
... sampling EEG with 64 channel display capability. ... as well as epilepsy centers, sleep labs ... for automatic spike and seizure detection, and ... Data Acquisition ,The Neurofax EEG-1100 is available ...
Medicine Products: